gutflix
GI learning, personalised

Summary

ARTIFICIAL INTELLIGENCE-ASSISTED ENDOSCOPY FOR GASTRIC CANCER SCREENING IN CHINA: A COST EFFECTIVENESS ANALYSIS

Honggang Yu

UEG Week Copenhagen 2023 | Poster

October 16, 2023

A cost-effectiveness analysis from China found that AI-assisted gastroscopy screening (IREAD) for gastric cancer was both cost-saving compared to conventional screening and cost-effective compared to no screening in high-risk individuals aged 40 years and older.

KEY POINTS

- IREAD-assisted screening had an average cost of $3482 per patient and effectiveness of 16.05 QALY, compared to $3530 and 16.04 QALY for conventional screening, and $3177 and 16.03 QALY for non-screening
- The ICER for IREAD-assisted screening was $14932.12 per QALY versus non-screening, below the willingness-to-pay threshold of $25,704 per QALY, making it cost-effective
- At the national level, replacing conventional screening with IREAD-assisted screening could prevent 3372 gastric cancer cases and 917 deaths annually while saving $1.75 billion
- IREAD was cost-saving compared to conventional screening across all screening interval scenarios tested (1 to 3 years) and remained cost-effective compared to non-screening
- This study would be of interest to health policy makers, health economists, and gastroenterologists involved in gastric cancer screening programs in high-risk populations

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/b0d7fc8a-743b-11ee-bf44-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.